You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 132 No. 10, October 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Combined Liver—Total Bowel Transplantation Has No Immunologic Advantage Over Total Bowel Transplantation Alone

A Prospective Study in a Porcine Model

Rainer W. G. Gruessner, MD, PhD; Raouf E. Nakhleh, MD; Enrico Benedetti, MD; Jacques Pirenne, MD, PhD; Kumar G. Belani, MD; David Beebe, MD; Richard Carr, MD; Christoph Troppmann, MD; Angelika C. Gruessner, MS, PhD

Arch Surg. 1997;132(10):1077-1085.


Abstract

Background
Rejection remains a major obstacle to successful bowel transplantation in humans. It has been suggested that a simultaneous liver transplant would shield the bowel graft from immunologic attack, but the liver shortage would be aggravated. In a preclinical model, we studied the influence of simultaneous liver grafting by comparing the incidence of early bowel rejection after combined liver—total (small- and large-) bowel transplants vs total bowel transplants alone.

Methods
We assessed the incidence of early posttransplant rejection, graft-vs-host disease, and infection after combined liver—total bowel transplants (group 1, n=10) and total bowel transplants alone (group 2, n=9) in outbred Yorkshire Landrace pigs. Liver and bowel grafts were transplanted orthotopically with portal vein drainage after recipient hepatectomy (group 1) and total enterectomy (groups 1 and 2). Posttransplant immunosuppression was performed with intravenous tacrolimus (whole blood levels, 15 to 30 ng/mL) and prednisolone. In groups 1 and 2, bowel biopsy specimens from the ileostomy were obtained daily. In group 1, liver biopsy specimens were obtained weekly. Rejection was graded according to a 4-point scoring system (none, mild, moderate, and severe).

Results
Overall graft survival at days 7, 14, and 21 was 89%, 44%, and 11%, respectively, in group 1 vs 100%, 100%, and 86%, respectively, in group 2 (P<.001). Death rates owing to (irreversible) rejection at days 7, 14, and 21 were 0% in groups 1 and 2 (P=.48). Grading of bowel rejection episodes, based on the results of daily biopsy specimans, was not significantly different between the groups whether on individual days or overall. In group 1, the incidence of liver rejection episodes was as high as 66% (day 14 and at autopsy). At autopsy, generalized graft-vs-host disease (skin, native intestine, and native liver) was noted in 55% of group 1 and 43% of group 2 pigs (P=.55). Graft-vs-host disease was noted concurrently with rejection episodes of the liver or bowel grafts.

Conclusions
Simultaneous liver grafting did not further reduce the incidence of early bowel rejection or graft-vs-host disease when compared with total bowel transplants alone. Based on the results of this preclinical study, simultaneous liver grafting is not indicated for patients with short-bowel syndrome and normal liver function.

Arch Surg. 1997;132:1077-1085



Author Affiliations

From the Departments of Surgery (Drs R. Gruessner, Benedetti, Pirenne, Troppmann, and A. Gruessner) and Anesthesiology (Drs Belani, Beebe, and Carr), University of Minnesota, Minneapolis, and the Department of Pathology (Dr Nakhleh), Henry Ford Hospital, Detroit, Mich.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.